- Global Pharma News & Resources

Eckert & Ziegler off to a strong start in 2019

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results/Quarterly / Interim Statement

07.05.2019 / 07:45
The issuer is solely responsible for the content of this announcement.

Berlin, 7 May 2019. Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, increased its sales in the first quarter 2019 by 22 % to EUR 43.5 million year on year. Net income from continuing operations achieved EUR 5.8 million and thus increased by EUR 3.5 million or 152 % year on year. Earnings per share increased by EUR 0.70 to EUR 1.14. The causes of the higher net profit for the year were growth in sales and a more favorable product mix.

The greatest spurt of growth was recorded in the Radiopharma segment, which was essentially driven by continuing attractive sales of pharmaceutical radioisotopes to reach a level of EUR 10.0 million, an increase of EUR 3.4 million or 52% year-on-year. The Isotope Products segment also achieved a clear increase in sales of 18% or EUR 4.2 million, reaching a total of EUR 28.2 million. The Radiation Therapy segment, however, recorded a slight drop in sales, achieving EUR 6.4 million, which represents a fall of around 6% year-on-year.

The operating cash flow rose significantly by EUR 6.4 million to EUR 7.7 million. Decisive factors here were the increase of EUR 3.5 million in the result for the period and the non-cash effects from the depreciation of assets, which rose by EUR 0.7 million. Overall, cash and cash equivalents as of March 31, 2019 had increased by EUR 5.9 million since the end of 2018, and now amount to EUR 60.1 million.

The management is maintaining its projection that an annual surplus of approximately EUR 3.50 per share and sales of approximately EUR 180 million will be achieved. This outlook is based on the assumption that the euro exchange rate does not exceed $ 1.20.

The complete financial statements can be viewed here:

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.
Contributing to saving lives.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138,,

07.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
13125 Berlin
Phone: 49 30 941084-138
Fax: 49 30 941084-112
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 807579

End of News DGAP News Service

Editor Details

Last Updated: 07-May-2019